These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis? Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009 [TBL] [Abstract][Full Text] [Related]
3. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy. Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586 [TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Pierantonelli I; Svegliati-Baroni G Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287 [TBL] [Abstract][Full Text] [Related]
5. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN Elife; 2023 Jan; 12():. PubMed ID: 36648330 [TBL] [Abstract][Full Text] [Related]
6. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303 [TBL] [Abstract][Full Text] [Related]
7. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137 [TBL] [Abstract][Full Text] [Related]
8. Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. Xu L; Nagata N; Ota T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775341 [TBL] [Abstract][Full Text] [Related]
9. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291 [TBL] [Abstract][Full Text] [Related]
10. Molecular pathways of nonalcoholic fatty liver disease development and progression. Bessone F; Razori MV; Roma MG Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320 [TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454 [TBL] [Abstract][Full Text] [Related]
12. Non-Alcoholic Fatty Liver Disease. Engin A Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211 [TBL] [Abstract][Full Text] [Related]
13. Key molecular pathways in the progression of non-alcoholic steatohepatitis. Tong J; Guo JJ Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8515-8522. PubMed ID: 31646583 [TBL] [Abstract][Full Text] [Related]
14. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H Cells; 2021 Oct; 10(11):. PubMed ID: 34831031 [TBL] [Abstract][Full Text] [Related]
15. Immune-metabolic interactions in homeostasis and the progression to NASH. Hoogerland JA; Staels B; Dombrowicz D Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913 [TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331 [TBL] [Abstract][Full Text] [Related]
17. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794 [TBL] [Abstract][Full Text] [Related]
18. Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death. Frietze KK; Brown AM; Das D; Franks RG; Cunningham JL; Hayward M; Nickels JT Autophagy; 2022 Jan; 18(1):142-160. PubMed ID: 33966599 [TBL] [Abstract][Full Text] [Related]
19. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Handa P; Maliken BD; Nelson JE; Morgan-Stevenson V; Messner DJ; Dhillon BK; Klintworth HM; Beauchamp M; Yeh MM; Elfers CT; Roth CL; Kowdley KV Hepatology; 2014 Jul; 60(1):133-45. PubMed ID: 24464605 [TBL] [Abstract][Full Text] [Related]
20. Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet. Baiges-Gaya G; Fernández-Arroyo S; Luciano-Mateo F; Cabré N; Rodríguez-Tomàs E; Hernández-Aguilera A; Castañé H; Romeu M; Nogués MR; Camps J; Joven J J Nutr Biochem; 2021 Mar; 89():108559. PubMed ID: 33264665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]